Alzheimer's Association

In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings."

The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.

Spurred by newly available beta-amyloid-targeting drugs, hospitals are exploring how to diagnose Alzheimer's patients early and determine their treatment.